Research Analysts Offer Predictions for LXRX FY2026 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at HC Wainwright increased their FY2026 earnings estimates for Lexicon Pharmaceuticals in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of ($0.14) per share for the year, up from their prior forecast of ($0.15). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.17) EPS and FY2030 earnings at ($0.09) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%.

Other analysts have also recently issued reports about the company. Wall Street Zen raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Sunday. Citigroup upped their price objective on Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Cantor Fitzgerald initiated coverage on Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average target price of $5.80.

Lexicon Pharmaceuticals Trading Up 2.2%

Shares of LXRX stock opened at $1.82 on Monday. Lexicon Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $2.68. The company has a market capitalization of $809.83 million, a PE ratio of -13.00 and a beta of 1.10. The firm has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $1.89. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. Siren L.L.C. lifted its holdings in shares of Lexicon Pharmaceuticals by 13.8% during the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock worth $69,113,000 after acquiring an additional 5,384,615 shares during the period. Renaissance Technologies LLC lifted its stake in Lexicon Pharmaceuticals by 508.0% during the first quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 1,337,246 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Lexicon Pharmaceuticals during the first quarter worth $1,170,000. Bank of New York Mellon Corp bought a new stake in Lexicon Pharmaceuticals during the second quarter worth $1,365,000. Finally, Bank of America Corp DE boosted its holdings in shares of Lexicon Pharmaceuticals by 415.3% in the 1st quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company’s stock valued at $821,000 after purchasing an additional 424,006 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lexicon Pharmaceuticals

In other news, CEO Michael Exton acquired 30,064 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, November 6th. The shares were purchased at an average cost of $1.66 per share, for a total transaction of $49,906.24. Following the completion of the purchase, the chief executive officer directly owned 328,496 shares of the company’s stock, valued at approximately $545,303.36. This represents a 10.07% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 14.00% of the stock is owned by insiders.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.